4 / 38
Front-line EGFR TKI monotherapy vs.
combination
Trial
TKI
Combination
agent
N
mPFS (TKI vs
Combo), p
PFS HR
(95%CI)
ORR% (TKI vs
Combo)
Discontinuation for
AE-combo (%)
OS HR
(95%CI)
NEJ026
Erlotinib Bevacizumab
224 16.9 vs 13.3;
p=0.016
0.605
(0.42-0.88)
72 vs 66
30 vs 15
NR
JO25567 Erlotinib Bevacizumab
154 16.0 vs 9.7;
p=0.0015
0.54
(0.36-0.79)
69 vs 64
41 vs 18
0.81 (0.53-
1.23)
NEJ009
GCP
Gefitinib Carboplatin and
pemetrexed, +
maintenance pem
345 20.9 vs 11.2;
p<0.001
0.49
(0.39-0.63)
84 vs 67
10.7 vs 9.9
0.70 (0.52-
0.93)
Furuya N et al J Clin Oncol 2018 (abstract 9006); Seto T et al Lancet Oncol 2014; Yamamoto N et al J Clin Oncol 2018 (abstract 9007); Nakamura A et al J Clin
Oncol 2018 (abstract 9005) ;
NR, not reported; pem, pemetrexed